These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Additional hepatic Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988 [TBL] [Abstract][Full Text] [Related]
5. Integrin α Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808 [TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608 [TBL] [Abstract][Full Text] [Related]
7. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631 [TBL] [Abstract][Full Text] [Related]
8. High clinical and morphologic response using Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267 [TBL] [Abstract][Full Text] [Related]
9. Alpha and Beta Radiation for Theragnostics. Song H; Sgouros G PET Clin; 2024 Jul; 19(3):307-323. PubMed ID: 38688775 [TBL] [Abstract][Full Text] [Related]
10. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Kunikowska J; Królicki L; Hubalewska-Dydejczyk A; Mikołajczak R; Sowa-Staszczak A; Pawlak D Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1788-97. PubMed ID: 21553086 [TBL] [Abstract][Full Text] [Related]
11. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002 [TBL] [Abstract][Full Text] [Related]
12. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Braat AJAT; Bruijnen RCG; van Rooij R; Braat MNGJA; Wessels FJ; van Leeuwaarde RS; van Treijen MJC; de Herder WW; Hofland J; Tesselaar MET; de Jong HWAM; Lam MGEH Lancet Oncol; 2020 Apr; 21(4):561-570. PubMed ID: 32112737 [TBL] [Abstract][Full Text] [Related]
13. Hervás I; Bello P; Falgas M; Del Olmo MI; Torres I; Olivas C; Vera V; Oliván P; Yepes AM Rev Esp Med Nucl Imagen Mol; 2017; 36(2):91-98. PubMed ID: 27889527 [TBL] [Abstract][Full Text] [Related]
14. Cardiac metastases of neuroendocrine tumors treated with 177Lu DOTATATE peptide receptor radionuclide therapy or 131I-MIBG therapy. Makis W; McCann K; Bryanton M; McEwan AJ Clin Nucl Med; 2015 Dec; 40(12):962-4. PubMed ID: 26359563 [TBL] [Abstract][Full Text] [Related]
15. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114 [TBL] [Abstract][Full Text] [Related]
16. Radionuclide Therapy for Neuroendocrine Tumors. Cives M; Strosberg J Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446 [TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice. Sheikhbahaei S; Sadaghiani MS; Rowe SP; Solnes LB AJR Am J Roentgenol; 2021 Aug; 217(2):495-506. PubMed ID: 34076455 [No Abstract] [Full Text] [Related]
18. Evaluation of cytotoxic and tumor targeting capability of (177)Lu-DOTATATE-nanoparticles: a trailblazing strategy in peptide receptor radionuclide therapy. Arora G; Dubey P; Shukla J; Ghosh S; Bandopadhyaya G Ann Nucl Med; 2016 Jun; 30(5):334-45. PubMed ID: 26897009 [TBL] [Abstract][Full Text] [Related]
19. 90Y/177Lu-DOTATATE therapy: survival of the fittest? Brans B; Mottaghy FM; Kessels A Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1785-7. PubMed ID: 21755369 [No Abstract] [Full Text] [Related]
20. Orbital Metastases of Neuroendocrine Tumors Treated With 177Lu-DOTATATE PRRT or 131I-MIBG Therapies. Makis W; McCann K; McEwan AJ Clin Nucl Med; 2016 Feb; 41(2):137-41. PubMed ID: 26447382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]